research centers


Search results: Found 1

Listing 1 - 1 of 1
Sort by

Article
Efficacy & Safety of Repaglinide as Monotherapy or with Metformin in Achieving the Recommended Glycemic Targets of Type 2 Diabetes

Authors: Esam N. S. Al-Kirwi عصام الكروي --- Tawfeeq F. R. AL-Auqbi توفيق العقبي
Journal: Mustansiriya Medical Journal مجلة المستنصرية الطبية ISSN: 20701128 22274081 Year: 2008 Volume: 7 Issue: 1 Pages: 4-8
Publisher: Al-Mustansyriah University الجامعة المستنصرية

Loading...
Loading...
Abstract

AbstractObjectivesTo assess the efficacy and safety of Repaglinide in achieving the recommended glycemic targets in type 2 diabetes.MethodsSix months prospective interventional study (before and after treatment) was carried out on 125 type 2 diabetics treated by Repaglinide with/without metformin. Patients were interviewed three times, at the begining, after three and six months each time they were examined physically and investigated thoroughly.ResultsEfficacy and safety parameters, fasting plasma glucose (FPG), postprandial plasma glucose (PPG) and glycated hemoglobin (HbA1c) had shown a significant statistical reduction to meet the recommended glycemic control targets of the American Diabetes Association (ADA) and very close to the International Diabetes Federation, European Diabetes Policy Group (IDF) at the consecutive interviews. Lipid profiles values, Total cholesterol, LDL-C, HDL-C, non-HDL-C, triglyceride and atherogenic index (TC/ HDL-C ratio) were achieved significant statistical improvements.ConclusionsRepaglinide as monotherapy or in combination with metformin was safe, efficacious and well tolerated for lowering plasma glucose in type 2 diabetes, achieving the internationally recommended glycemic targets and improving the lipid profile values.

Keywords

Listing 1 - 1 of 1
Sort by
Narrow your search

Resource type

article (1)


Language

English (1)


Year
From To Submit

2008 (1)